131 related articles for article (PubMed ID: 12138332)
1. Effect of Micafungin (FK463) on Candida albicans adherence to epithelial cells.
Borg-von Zepelin M; Zaschke K; Gross U; Monod M; Müller FM
Chemotherapy; 2002 Jul; 48(3):148-53. PubMed ID: 12138332
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.
Maesaki S; Hossain MA; Miyazaki Y; Tomono K; Tashiro T; Kohno S
Antimicrob Agents Chemother; 2000 Jun; 44(6):1728-30. PubMed ID: 10817741
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.
Tawara S; Ikeda F; Maki K; Morishita Y; Otomo K; Teratani N; Goto T; Tomishima M; Ohki H; Yamada A; Kawabata K; Takasugi H; Sakane K; Tanaka H; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Jan; 44(1):57-62. PubMed ID: 10602723
[TBL] [Abstract][Full Text] [Related]
4. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
[TBL] [Abstract][Full Text] [Related]
5. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.
Mikamo H; Sato Y; Tamaya T
J Antimicrob Chemother; 2000 Sep; 46(3):485-7. PubMed ID: 10980180
[TBL] [Abstract][Full Text] [Related]
6. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide.
Nishiyama Y; Uchida K; Yamaguchi H
J Electron Microsc (Tokyo); 2002; 51(4):247-55. PubMed ID: 12227555
[TBL] [Abstract][Full Text] [Related]
7. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
8. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus.
Hatano K; Morishita Y; Nakai T; Ikeda F
J Antibiot (Tokyo); 2002 Feb; 55(2):219-22. PubMed ID: 12003006
[No Abstract] [Full Text] [Related]
9. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility.
Niimi K; Maki K; Ikeda F; Holmes AR; Lamping E; Niimi M; Monk BC; Cannon RD
Antimicrob Agents Chemother; 2006 Apr; 50(4):1148-55. PubMed ID: 16569823
[TBL] [Abstract][Full Text] [Related]
10. Micafungin activity against Candida albicans with diverse azole resistance phenotypes.
Richards TS; Oliver BG; White TC
J Antimicrob Chemother; 2008 Aug; 62(2):349-55. PubMed ID: 18436555
[TBL] [Abstract][Full Text] [Related]
11. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis.
Müller FM; Kurzai O; Hacker J; Frosch M; Mühlschlegel F
J Antimicrob Chemother; 2001 Nov; 48(5):713-5. PubMed ID: 11679561
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.
Ikeda F; Wakai Y; Matsumoto S; Maki K; Watabe E; Tawara S; Goto T; Watanabe Y; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Mar; 44(3):614-8. PubMed ID: 10681327
[TBL] [Abstract][Full Text] [Related]
13. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species.
Ramírez M; Serrano MC; Castro C; López E; Almeida C; Fernández A; Romero A; Martín-Mazuelos E
J Antimicrob Chemother; 2006 Oct; 58(4):861-3. PubMed ID: 16916868
[TBL] [Abstract][Full Text] [Related]
15. Deletions of the endocytic components VPS28 and VPS32 in Candida albicans lead to echinocandin and azole hypersensitivity.
Cornet M; Gaillardin C; Richard ML
Antimicrob Agents Chemother; 2006 Oct; 50(10):3492-5. PubMed ID: 17005841
[TBL] [Abstract][Full Text] [Related]
16. Glucan-associated protein modulations and ultrastructural changes of the cell wall in Candida albicans treated with micafungin, a water-soluble, lipopeptide antimycotic.
Angiolella L; Maras B; Stringaro AR; Arancia G; Mondello F; Girolamo A; Palamara AT; Cassone A
J Chemother; 2005 Aug; 17(4):409-16. PubMed ID: 16167521
[TBL] [Abstract][Full Text] [Related]
17. Increase of virulence and its phenotypic traits in drug-resistant strains of Candida albicans.
Angiolella L; Stringaro AR; De Bernardis F; Posteraro B; Bonito M; Toccacieli L; Torosantucci A; Colone M; Sanguinetti M; Cassone A; Palamara AT
Antimicrob Agents Chemother; 2008 Mar; 52(3):927-36. PubMed ID: 18180350
[TBL] [Abstract][Full Text] [Related]
18. [The future of antifungal agents. Non azole antifungal agents].
Maesaki S; Hossain MA; Sasaki E; Hashiguchi K; Higashiyama Y; Yoshitsugu Y; Tomono K; Tashiro T; Kohno S
Nihon Ishinkin Gakkai Zasshi; 1999; 40(3):157-61. PubMed ID: 10423510
[TBL] [Abstract][Full Text] [Related]
19. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.
Jacobsen MD; Whyte JA; Odds FC
Antimicrob Agents Chemother; 2007 May; 51(5):1882-4. PubMed ID: 17307974
[TBL] [Abstract][Full Text] [Related]
20. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
